Online inquiry

IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (CAT#: GTTS-WQ6541MR)

This product GTTS-WQ6541MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Uveitis research.

Specifications
Product type	mRNA
Modified bases	5-Methyl-CTP & Pseudo-UTP
5' Cap	Cap 0
Species	Homo sapiens
RefSeq	NM_000594.4
Applications	Gene therapy research
Format	Powder
Quantity	100 µg
Purification	oligo-dT affinity purification

Target Gene
Gene ID	7124
UniProt ID	P01375

Download
Download resources about mRNA therapeutics development to boost your research.

CUSTOMER REVIEWS and Q&As
There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6541MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT	Product Name	Product Type	CDs
GTTS-WQ11682MR	IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, Pseudo-UTP, 120 nt-poly(A))	mRNA	MHAB5553A
GTTS-WQ13423MR	IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))	mRNA	PRO132365
GTTS-WQ15306MR	IVTScrip™ mRNA-Anti-TNF, TNFR55-Ig1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	TNFR55-Ig1
GTTS-WQ14301MR	IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	RG-7221
GTTS-WQ4310MR	IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))	mRNA	BIVV009
GTTS-WQ8103MR	IVTScrip™ mRNA-Anti-TNFRSF10B, HGS-ETR2(Cap 0, Pseudo-UTP, 120 nt-poly(A))	mRNA	HGS-ETR2
GTTS-WQ2570MR	IVTScrip™ mRNA-Anti-IGF1R, AMG 479(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))	mRNA	AMG 479
GTTS-WQ984MR	IVTScrip™ mRNA-Anti-TNFRSF4, ABBV-368(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))	mRNA	ABBV-368

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST